Clinical development plan: tea extracts. Green tea polyphenols. Epigallocatechin gallate.
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004285:Dogs; D017277:Drug Approval; D005260:Female; D005419:Flavonoids; D006801:Humans; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D009374:Neoplasms, Experimental / Q000517:prevention & control; D010636:Phenols / Q000494:pharmacology / Q000627:therapeutic use*; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D011108:Polymers / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D012107:Research Design; D013662:Tea / Q000737:chemistry*
D016588:Anticarcinogenic Agents; D005419:Flavonoids; D010636:Phenols; D010936:Plant Extracts; D011108:Polymers; D013662:Tea; D002392:Catechin; C045651:epigallocatechin gallate